Background
==========

Based on the epidemiologic classification in terms of their risk to induce cervical cancer, human papillomaviruses (HPV) can be divided into 3 groups: "high-risk" genotypes associated with a greater risk of developing cancer, "low-risk" genotypes associated with low grade cell changes or benign epithelium proliferations in the genital area, but not with cancer, and "probable high-risk" genotypes from which there is not enough data about their relationship with cervical cancer to classify them \[[@B1]\].

About 15 genotypes are classified as high-risk types, and two of them (16 and 18) cause over 70% of all cervical cancer cases \[[@B2],[@B3]\]. Nucleotide variability of these genotypes has been largely studied and different molecular variants were described \[[@B4],[@B5]\]. These variants differ in their biological and chemical properties \[[@B6]-[@B8]\], and therefore, may become an important risk factor in cervical cancer due to possible differences in pathogenicity.

Most authors classified variants based on the phylogenetic analysis of one genomic region nucleotide variations \[[@B9]\]. Nevertheless, some publications have confirmed the presence of recombination in HPV samples \[[@B10],[@B11]\]. This event may occur due to a homologous recombination or to a repeated infection of the same HPV genotype but different variant and it is more often found since coinfections with more than one HPV type are becoming a usual finding \[[@B12]-[@B14]\]. Therefore, it should be essential to determine HPV variants analyzing different genomic regions and multiple infections.

There are very few epidemiological national studies in Spain and all of them refer to HPV 16 which is the most investigated HPV type worldwide. However, there is no previous national work related to HPV 18 nucleotide variability, which is the second most prevalent HPV genotype found in cervical cancer.

The aim of the present study was: i) to characterize the genetic variability of HPV 18 in 5 genomic regions: E6, E7, E4, L1 and the Upstream Regulatory Region (URR), working with both single infection and multiple HPV infection samples, ii) assess the prevalence of HPV 18 variants in our region and look for existence of recombination, and iii) analyze the relationship between variants and types of lesion.

Results
=======

Samples collected
-----------------

Since 2007 to 2010, a total of 1085 positive samples for HPV were received and analyzed. HPV 18 was detected in 65 samples (6%). Forty-four patients consented to have their samples analyzed and studied, so this study was based on their samples: 10 single HPV infections (22.7%) and 34 multiple HPV infections (77.3%).

We were able to amplify HPV DNA in 43/44 samples for E6 region, 41/44 for E7, 35/44 for E4, 43/44 for L1 region and 44/44 for URR region. All PCR products were sequenced and sequences from each region were submitted to GenBank.

Nucleotide variations
---------------------

Variant distribution was determined through E6, E7, E4, L1 and URR sequences. Genetic analysis of the regions revealed a total of 56 nucleotide variations (Figure [1](#F1){ref-type="fig"}).

![**Nucleotide sequence variations among HPV isolates.** Numbering refers to the first nucleotide of the HPV 18 reference genome (accession number NC001357). Each row indicates the isolate identification and the PCR nucleotide sequence alignment compared to the reference. Isolates EF202143-EF202155 are HPV 18 known variant sequences which belong to Asian-amerindian lineage, African and European lineage. Nucleotide positions where a substitution leads to a change of amino acid are highlighted in gray. In the first column, samples that are highlighted in gray correspond to single HPV infection samples, whereas not highlighted samples correspond to multiple HPV infections. Dashes indicate absence of nucleotide sequence data. Recombinant variants are indicated by an asterisk.](1743-422X-9-258-1){#F1}

In the *E6* gene nine nucleotide variations were detected. Six of them were specific to the African lineage: T317C (6/10 African variants), T251C (9/10), A548G, G266A and G374A (present in all African isolates) and C342T (5/10 African variants) which lead to a non-synonymous amino acid alteration His/Tyr. A non-synonymous substitution T318C (Tyr/His) was found to be specific to the European lineage (2/25 European isolates), while the synonymous substitution C549A was detected among the three different branches (35/43 sequenced *E6* amplimers). In our study, C287G was observed in all HPV 18 isolates.

*E7* gene genetic variability analysis revealed five nucleotides substitutions. Three nucleotide variations were specific for the African lineage: C665T (3/10 African variants), C593T (His/Tyr), C640C and T864G (Asn/Ser). All of them but C665T and T864G were present in all African variants. One synonymous substitution (C751T) was detected in both European and Asian-amerindian isolates (26/34 non-African variants).

*E4* gene analysis presented most nucleotide variations (17 substitutions) and almost half of them (8/17) lead to amino acid changes. All African variants showed 4 non-synonymous substitutions (C3558A His/Gln, C3578T Ser/Leu, A3586C Ser/Arg and T3593G Ile/Ser), one synonymous variation (T3534C) and a deletion of 6 amino acids (3627--3632). European variants showed 4 specific non synonymous substitutions G3482A (Ser/Asn, 3/25 isolates), T3563A (Leu/Gln, 4/25), C3617T (Ser/Leu, 4/25) and C3630G (His/Gln, all European isolates). Two non-synonymous substitutions were also detected in two European isolates: T3492A and C3615T.

*L1* gene and URR sequence analysis demonstrated the presence of substitutions C6842G and T7592C in all our isolates.

Most nucleotide variations found in our study have been already described in literature except for T318C, C665T, C3615T, C3617T, G6897A, G6993A, A7000T/C, T7001C, T7007G and T7765G. Only substitutions in positions 318 and 3617 lead to amino acid changes (Tir/His and Ser/Leu, respectively). T318C substitution was present in 2 European isolates whereas C3617T nucleotide change was not specific to any lineage and was detected in 5 samples.

HPV variants
------------

In our study, the predominant variant found was the European (25/44 samples) followed by the African (10/44) and the Asian-amerindian variants (5/44).

Phylogenetic analysis of the all regions studied showed that European and Asian-amerindian lineages formed closely related nodes as well as a maximal nucleotide diversity between African and non-African variants (Figure [2](#F2){ref-type="fig"}) (Additional file [1](#S1){ref-type="supplementary-material"}).

![**Phylogenetic tree of the HPV 18 isolates.** E6, E7, E4, L1 and URR nucleotide sequences of isolates using the Bayesian inference method implemented in MrBayes 3.1. Isolates EF202143-EF202155 are included as HPV 18 reference variant sequences which belong to Asian-amerindian lineage, African and European lineage.](1743-422X-9-258-2){#F2}

Isolates which showed nucleotide diversity from the three branches (European, Asian-amerindian and African) - LSM3, LSCM, LSCE, LSMK1, LSCR, LSMH1, LSC5, LSM7 and LSCB -- were analyzed for possible recombination (Table [1](#T1){ref-type="table"}).

###### 

Evidence for recombinant samples

  ----------------------------------------------------------------------------------------------------
  **Sample \\ Gene**    **E6**   **E7**   **E4**   **L1**   **URR**        **Program inference**
  -------------------- -------- -------- -------- -------- --------- ---------------------------------
  LSM3                    Af       Af       X        X         E        No recombination detected.

  LSCE                    Af       Af       E        E         E      Maxchi detected recombination.\
                                                                        (LSCM is one of the donors)

  LSMK1                  AsA       E        Af       E        Af      Maxchi detected recombination.\
                                                                      (LSCI and LSCR1 are the donors)

  LSCR                    E        E        E        E         E        No recombination detected.

  LSMH1                   E        E        E        E         E        No recombination detected.

  LSC5                    E        E        E        E         E        No recombination detected.

  LSM7                    E        E        E        E         E        No recombination detected.

  LSCB                   AsA       E        E        E         E        No recombination detected.

  LSCM                    Af       E        Af       Af        E        No recombination detected.
  ----------------------------------------------------------------------------------------------------

Isolates analyzed for possible recombination. Phylogenetic trees were constructed for each sequenced region and isolates were classified as Asian-amerindian (AsA), European (E) or African (Af) variants. RDP, Maxchi and Chimaera were used for the detection of recombination. URR: Upstream regulatory region, X: absence of data.

Phylogenetic trees were constructed for each sequenced region from these isolates and we found that samples LSCR, LSMH1, LSC5 and LSM7 belonged to the European branch in all regions and therefore, were classified as Europeans. Isolate LSCB belonged to the European lineage in all regions but in *E6* (Asian-amerindian) due to the lack of one nucleotide substitution (C549A). This sample was also classified as European.

Samples LSM3, LSCM, LSCE, LSMK1 belonged to the African branch in some regions but were classified as European in others (Table [1](#T1){ref-type="table"}).

RDP \[[@B15]\], Maxchi \[[@B16]\] and Chimaera were used for the detection of recombination in these 9 samples and only 2 of them were found to be recombinant, one single (LSMK1) and one multiple HPV infection (LCE) (Table [1](#T1){ref-type="table"}). LSCM and LSM3 were classified as X variants (unknown).

Variants, type of lesion and infection type
-------------------------------------------

Out of 44 samples, 32 were classified by pathologists as normal (no lesion was found), 9 samples were diagnosed as L-SIL while presence of H-SIL was detected in 3 specimens.

High grade lesions only presented African variants (2/3 isolates, 66.7%) and variants that presented both African and European substitutions (1/3 isolates, 33.3%) whereas most European and Asian-amerindian variants were detected in negative cytologies (Table [2](#T2){ref-type="table"}).

###### 

Human papillomavirus 18 variants vs type of lesion

  **Variants \\ Type of Lesion**     **Neg**    **L-SIL**   **H-SIL**
  -------------------------------- ----------- ----------- -----------
  European                          **71.0%**     3.3%         0%
  Asian-amerindian                    12.9%       1.1%         0%
  African                             12.9%       4.4%      **100%**
  Recombinant                         3.2%        1.1%         0%

Neg: no lesion, L-SIL: low-grade squamous intrapehitelial lesion, H-SIL: high-grade squamous intraephitelial lesion.

Presence of lesions associated with non-European variants was found to be statistically significant (p = 0.01053). Nevertheless, there was not a statistically significant association between type of infections (single vs multiple) and presence of lesions (p = 0.18078).

Discussion
==========

There are almost no epidemiologic studies about HPV 18 variants carried out in Spain and even though national HPV prevalence is low, it cannot be forgotten that this genotype together with genotype 16 cause 70% of cervical cancer cases.

Many authors confirm that distribution of HPV variants is related to geographic or race distribution \[[@B6],[@B17]\] and therefore, Spain should expect predominance of European variant, followed by African and Asian-amerindian variants. Our results show concordance with this stating: 25 European variants (56.8%), 10 African (22.7%) and 5 Asian-amerindian variants (11.4%).

HPV 18 has been associated with both recurrent lesions with very bad clinical prognosis \[[@B18]\] and benign lesions \[[@B19]\]. This fact may reflect the oncogenic potential difference among variants. Hecht et al \[[@B20]\] identified a HPV 18 variant with lower oncogenic potential due to its absence in cervical cancer but presence in 40% of intraepithelial lesions. Villa et al \[[@B21]\] suggested that non-European HPV 18 variants persisted more frequently and were more associated with pre-invasive lesions. Since then, most studies confirm that different variants of the same genotype differ in their pathogenic characteristics and therefore, nucleotide substitutions may play an important role. Our study results show concordance with these statements as African variants and variants where most of specific-african substitutions were detected were the only type of variants detected in H-SIL.

Most nucleotide changes reported in our study have been previously described and some of them are of particular importance. In URR, the mutation A41G is located in the Sp-1 binding site and isolates with this nucleotide variation have shown to have an increased transcriptional activity \[[@B22]\]. Variations in positions 41 and 104 modulate Sp1 and YY1 activities and are associated to a higher activity of the E6/E7 promoter. Patients with T104C substitution are less likely to present tumour recurrence \[[@B23]\]. Other nucleotide changes like T7651C, A7658C and C7726T also lay within transcription factor binding sites.

Substitutions C287G, C6842G and T7592C were found in all our isolates. Variation C6842G has been previously reported as error in the original sequence \[[@B24]\], and H. Arias--Pulido et al. sequenced the original reference HPV 18 plasmid (provided by E-M de Villiers, Deutsches Krebsforschungzentrum, Germany) and observed the substitution T7592C \[[@B25]\], so it is considered as a sequencing error in the original HPV 18 reference sequence report.

Furthermore, ten "new" nucleotide variations have been detected and two of them were non-synonymous and lead to amino acid changes (T318C and C3617T, Tir/His and Ser/Leu, respectively).

Knowledge on HPV variants and their nucleotide variability is essential for three main reasons: i) nucleotide variations may interfere with the viral oncogenic potential, ii) host cellular immune response can be different when there are substitutions in the amino acids on the viral capsid which may be relevant for the vaccination, iii) HPV infections with a variant may not give immunological protection against a subsequent infection with other variant of the same genotype.

Nowadays, HPV variants recombination has already been described and it is more often found since coinfection with more than one HPV type prevalence is not a unusual finding \[[@B10]\].

In our study we detected 2 recombinant variants (4.5%) which might have been missed or wrong classified if only amplifying one genomic region. Furthermore, non-recombinant samples as LSCM or LSM3 showed specific-african substitutions in some regions (for example E6) whereas they would be classified as european variants when only analyzing nucleotide variation in URR. Therefore, characterizing more than one genomic region may be essential in order to detect recombination and classify HPV variants properly.

We amplified URR and *E6*, *E7* and *L1*genes from at least 93% of samples. However, when characterizing E4 region, we were only able to amplify 35 samples. *E4* gene is generally disrupted during DNA integration into the host genome and this disruption may explain the inability to amplify *E4* gene in some of our samples.

In conclusion, data and knowledge on geographic HPV intratypic variants distribution might help to establish a data base about the diversity and pathogenicity of different HPV variants, which may help to design and optimize diagnostics protocols in order to reduce the disease.

Methods
=======

Recruitment of participants
---------------------------

Clinical Microbiology and Infection Control Department at Basurto University Hospital (Basque Country, North of Spain) analyzed samples which were remitted from different Hospital Services, especially the Consultation of Sexually Transmitted Diseases and the Department of Obstetrics and Gynecology, from 2007 to 2010.

All samples were collected from patients with clinical manifestations of HPV related infections. Lesions were classified by pathologists into three categories: negative (no lesion was found), low-grade squamous intraepithelial lesion (L-SIL) or high-grade squamous intraepithelial lesion (H-SIL).

Molecular genotyping was carried out using "Linear Array HPV Genotyping Test" kit (Roche Molecular Diagnostics). In our study, we analyzed positive samples for HPV genotype 18 (both single infections and multiple HPV infections) from patients who had given written, informed consent.

Genomic DNA extraction
----------------------

DNA extraction was performed by QIAamp DNA mini Kit (Qiagen, Hilden, Germany), according to the manufacturer´s instructions. Extracted DNA was eluted with 200 μl AE buffer and stored at −20°C until amplification.

PCR amplification and sequencing
--------------------------------

Amplification of HPV *E6, E7, E4* genes and the URR was performed using type-specific primers designed according to HPV 18 genome prototype sequence (GenBank accession number NC001357). The URR was amplified using 2 primer sets. In order to amplify L1 region, consensus HPV primers were used (Table [3](#T3){ref-type="table"}).

###### 

Polymerase chain reaction characteristics for Human papillomavirus 18

            **Primer sequence (5′ -- 3′)**    **Annealing Temp/Cycles**   **Nucleotides amplified\***   **Amplicon size**
  --------- -------------------------------- --------------------------- ----------------------------- -------------------
  E6 F      AGTAACCGAAAACGGTCGGGA                  55°C/40 cycles                   38-491                   454 pb
  E6 R      GTTGTGAAATCGTCGTTTTTCA                                                                               
  E7 F      TGAAAAACGACGATTTCACAAC                 55°C/40 cycles                   470-931                  462 pb
  E7 R      ACCTTCTGGATCAGCCATTG                                                                                 
  E4 F      GTAAAGGAAGGGTACAACACG                  57°C/35 cycles                  3309-3792                 484 pb
  E4 R      CTGTCCAATGCCAGGTGGA                                                                                  
  LCR 1 F   TCGGTTGCCTTTGGCTTAT                    55°C/40 cycles                  7465-7775                 311 pb
  LCR 1 R   AAGGGTAGACAGAATGTTGGACA                55°C/40 cycles                  7718-163                  303 pb
  LCR 2 F   GCTAATTGCATACTTGGCTTG                                                                                
  LCR 2 R   TCCGTGCACAGATCAGGTAG                                                                                 
  MY11      GCACAGGGTCATAACAATGG                   55°C/40 cycles                  6558-7012                 455 pb
  MY09      CGTCCAAGGGATATTGATC                                                                                  
  L1 seq    ACAGTCTCCTGTACCTGGG                                                                                  

\*Position numbering refers to the first nucleotide of the HPV 18 reference genome (accession number NC001357). F: forward primer, R: reverse primer.

PCR was performed in 30 μl of reaction mixture containing 10 × PCR buffer, 25 mmol/L MgCl~2~, 25 mmol/L of each deoxynucleoside, 100 pmol/L of sense and anti-sense primer, 5 μl of template DNA and 2,5 U of Taq DNA polymerase (Qiagen).

The thermal program started with a pre-heat of 95°C for 15 min, followed by 35--40 cycles of suitable annealing temperature which depended on the primers and finished with a final extension at 72°C for 10 min (Table [3](#T3){ref-type="table"}).

PCR products were confirmed based on specific bands of amplified DNA presence in agarose gel (2%). Afterwards, amplimers were automatically sequenced using the "Big Dye Terminator Cycle Sequencing kit" (Applied Biosystems) according to the manufacturer´s instructions.

For E6, E7, E4 and URR amplicons the same forward specific primers as those used in amplification were chosen as sequencing primers. In the L1 region, a specific primer was used in order to sequence HPV 18 and not other HPV types present in cases of multiple infection (Table [3](#T3){ref-type="table"}).

Nucleotide variations, phylogenetic analysis: variants and recombination
------------------------------------------------------------------------

HPV sequences were aligned and compared to the HPV 18 prototype sequence which belongs to the Asian-amerindian lineage (accession number NC001357), using BioEdit Sequence Alignment Editor v7.0.4.1 and Clustal W (<http://www.genome.jp/tools/clustalw/>).

Amplification and sequencing of the samples were repeated to confirm nucleotide variations which were present in less than three isolates.

Sequences were assigned to a lineage on the basis of their similarity to HPV 18 known variant sequences \[[@B26]\] which belong to Asian-amerindian lineage (GenBank accession numbers: EF202143 - EF202146), African (EF202152 - EF202155) and European lineage (EF202147- EF202149, EF202151). Phylogenetic trees were built using the Bayesian inference method implemented in MrBayes 3.1 \[[@B27]\] and three methods (all implemented in RDP3 \[[@B15]\]) were used for the detection of recombination (RDP \[[@B15]\], Maxchi \[[@B16]\] and Chimaera) to analyze isolates which did not adjust to the clusters.

Lesions
-------

Association of lesions and variants or infection type (single HPV vs multiple HPV infection) was analyzed. Fisher exact test was used for statistically significant association.

GenBank accession numbers
-------------------------

The following are the GenBank accession numbers for all the sequences used in this analysis. X indicates absence of nucleotide sequence data Table [4](#T4){ref-type="table"}.

###### 

GeneBank accession numbers for the sequenced isolates

                                                                 
  ------------- ---------- ---------- ---------- ---------- ----------
  **Isolate**       E6         E7         E4         L1        URR
  **LSM1**       JN416211   JN416162      X       JN416262   JN416313
  **LSM2**       JN416212   JN416163   JN416121   JN416263   JN416314
  **LSM3**       JN416213   JN416164      X          X       JN416315
  **LSM4**       JN416214   JN416165   JN416122   JN416264   JN416316
  **LSC5**       JN416215   JN416166   JN416123   JN416265   JN416317
  **LSM6**       JN416216      X          X       JN416266   JN416318
  **LSM7**       JN416217   JN416167   JN416124   JN416267   JN416319
  **LSC9**       JN416219   JN416169   JN416125   JN416269   JN416321
  **LSCA**       JN416220   JN416170      X       JN416270   JN416322
  **LSCB**       JN416221   JN416171   JN416126   JN416271   JN416323
  **LSCC**       JN416222   JN416172   JN416127   JN416272   JN416324
  **LSCD**       JN416223   JN416173      X       JN416273   JN416325
  **LSCE**       JN416224   JN416174   JN416128   JN416274   JN416326
  **LSCF**          X          X          X       JN416275   JN416327
  **LSCG**       JN416225   JN416175      X       JN416276   JN416328
  **LSCH**       JN416226   JN416176   JN416129   JN416277   JN416329
  **LSCI**       JN416227   JN416177   JN416130   JN416278   JN416330
  **LSCJ**       JN416228   JN416178   JN416131   JN416279   JN416331
  **LSCK**       JN416229   JN416179   JN416132   JN416280   JN416332
  **LSCL**       JN416230   JN416180   JN416133   JN416281   JN416333
  **LSCM**       JN416231   JN416181   JN416134   JN416282   JN416334
  **LSCP**       JN416232   JN416182   JN416135   JN416283   JN416335
  **LSCR**       JN416234   JN416184   JN416137   JN416285   JN416337
  **LSCS**       JN416235      X       JN416138   JN416286   JN416338
  **LSCW**       JN416238   JN416187   JN416141   JN416289   JN416341
  **LSCX**       JN416239   JN416188   JN416142   JN416290   JN416342
  **LSCY**       JN416240   JN416189   JN416143   JN416291   JN416343
  **LSCA1**      JN416241   JN416190   JN416144   JN416292   JN416344
  **LSCC1**      JN416243   JN416192   JN416146   JN416294   JN416346
  **LSCE1**      JN416245   JN416194      X       JN416296   JN416348
  **LSMF1**      JN416246   JN416195   JN416147   JN416297   JN416349
  **LSMG1**      JN416247   JN416196   JN416148   JN416298   JN416350
  **LSCH1**      JN416248   JN416197   JN416149   JN416299   JN416351
  **LSCI1**      JN416249   JN416198   JN416150   JN416300   JN416352
  **LSCJ1**      JN416250   JN416199   JN416151   JN416301   JN416353
  **LSMK1**      JN416251   JN416200   JN416152   JN416302   JN416354
  **LSML1**      JN416252   JN416201   JN416153   JN416303   JN416355
  **LSCM1**      JN416253   JN416202   JN416154   JN416304   JN416356
  **LSCP1**      JN416256   JN416205   JN416157   JN416307   JN416359
  **LSCQ1**      JN416257   JN416206   JN416158   JN416308   JN416360
  **LSCR1**      JN416258   JN416207   JN416159   JN416309   JN416361
  **LSCS1**      JN416259   JN416208   JN416160   JN416310   JN416362
  **LSCT1**      JN416260   JN416209      X       JN416311   JN416363
  **LSCU1**      JN416261   JN416210   JN416161   JN416312   JN416364
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